Drug Profile


Alternative Names: ADI; ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Peglyated arginine deiminase - Phoenix Pharmacologics; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Polaris Pharmaceuticals; University of Miami
  • Class Antineoplastics; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II/III Mesothelioma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma; Small cell lung cancer
  • Phase I Solid tumours
  • No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Glioblastoma; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Viral infections

Most Recent Events

  • 08 Mar 2018 Washington University School of Medicine and Polaris Pharmaceuticals plans a phase II trial for Soft tissue sarcoma (Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA (NCT03449901), in March 2018
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Gastrointestinal-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral)
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Hepatocellular carcinoma(Combination therapy, First-line therapy, Late-stage disease) in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top